Diffuse Large B-Cell Lymphoma: Clinical Trials

24 trials for Diffuse Large B-Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 unknown. 24 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 224Unknown 24
Phase 11Unknown 1
Phase 31Unknown 1

Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Mitoxantrone Hydrochloride Liposome Injection - Diffuse Large B-Cell Lymphoma
Phase 2UnknownCSPC ZhongQi Pharmaceutical Technology Co., Ltd.1042023-07-102024-02-08
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
Orelabrutinib combined with R-CDOP regimen - Diffuse Large B-cell Lymphoma
Phase 2UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine622023-03-302024-03-04
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide - Diffuse Large B-cell Lymphoma
Phase 2UnknownJianfeng Zhou552022-10-102022-10-12
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
Chidamide, Azacitidine, obinutuzumab - Diffuse Large B-Cell Lymphoma
Phase 2UnknownThe First Affiliated Hospital of Soochow University232022-09-302023-04-21
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
Orelabrutinib, Rituximab, CHOP-like Regimen - Diffuse Large B-Cell Lymphoma
Phase 2UnknownThe First Affiliated Hospital of Soochow University462022-07-272023-02-03
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
Anlotinib Hydrochloride Capsules - Diffuse Large B-cell Lymphoma
Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.302021-04-012021-04-01
A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
TQ-B3525 tablets - Diffuse Large B-cell Lymphoma
Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.932021-01-202021-08-18
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
Toripalimab combine with Rituximab - Diffuse Large B-cell Lymphoma, Rituximab
Phase 2UnknownChinese Academy of Medical Sciences202020-06-152020-06-16
Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.
Sintilimab-R-CHOP - Diffuse Large B-Cell Lymphoma, Sintilimab
Phase 2UnknownChinese Academy of Medical Sciences302019-12-012019-12-11
BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT
Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma
Phase 2 / Phase 3UnknownNanfang Hospital, Southern Medical University1222017-07-052017-10-12
Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma
Abb-R-CHOP - Diffuse Large B-cell Lymphoma
Phase 2UnknownAsan Medical Center362016-12-072018-01-16
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Chidamide, Vinorelbine, Liposomal Doxorubicin or mitoxantrone - Diffuse Large B-cell Lymphoma
Phase 2UnknownHenan Cancer Hospital202016-05-012020-04-01
Chidamide Plus R-CHOP in Elderly DLBCL
Rituximab, Cyclophosphamide, Doxorubicin - Diffuse Large B-cell Lymphoma
Phase 2UnknownRuijin Hospital492016-04-012017-11-14
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Phase 1 / Phase 2UnknownNorthwestern University382015-10-282022-02-21
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Bortezomib, Gemcitabine, Dexamethasone - Diffuse Large B-cell Lymphoma
Phase 2UnknownRuijin Hospital302015-05-012017-11-14
Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)
Gemcitabine, Methylprednisolone, Rituximab - Diffuse Large B-Cell Lymphoma
Phase 2UnknownRoyal Marsden NHS Foundation Trust922013-09-012019-09-19
Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL
R-CHOP - Diffuse Large B-cell Lymphoma
Phase 2UnknownFudan University1962013-02-012013-03-05
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Rituximab, Temsirolimus, DHAP, intravenous - Diffuse Large B-Cell Lymphoma
Phase 2UnknownMathias Witzens-Harig882012-09-012016-10-27
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
R-GemOx - Diffuse Large B-cell Lymphoma
Phase 2UnknownThe First Affiliated Hospital with Nanjing Medical University602012-08-012019-02-15
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone - Diffuse Large B-cell Lymphoma
Phase 2UnknownPusan National University Hospital572012-08-012016-06-09

Showing 20 of 24. Sign in to see all of them.

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (24)  ·  Recurrence (2)  ·  Burkitt Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Plasmablastic Lymphoma (1)

Broader conditions

Hemic and Lymphatic Diseases (24)  ·  Immune System Diseases (24)  ·  Immunoproliferative Disorders (24)  ·  Lymphatic Diseases (24)  ·  Lymphoma (24)  ·  Lymphoproliferative Disorders (24)  ·  Neoplasms (24)  ·  Neoplasms by Histologic Type (24)  ·  Lymphoma, B-Cell (23)  ·  Lymphoma, Non-Hodgkin (23)  ·  Disease Attributes (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  DNA Virus Infections (1)  ·  Epstein-Barr Virus Infections (1)

Interventions

Rituximab (13)  ·  Cyclophosphamide (5)  ·  Doxorubicin (4)  ·  Prednisone (4)  ·  Vincristine (4)  ·  Gemcitabine (3)  ·  N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (3)  ·  Cisplatin (2)  ·  Cytarabine (2)  ·  Dexamethasone (2)  ·  Etoposide (2)  ·  Lenalidomide (2)  ·  R-CHOP protocol (2)  ·  Azacitidine (1)  ·  Bortezomib (1)

Sponsors

Asan Medical Center (2)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2)  ·  Chinese Academy of Medical Sciences (2)  ·  Fondazione Italiana Linfomi - ETS (2)  ·  Fudan University (2)  ·  Ruijin Hospital (2)  ·  The First Affiliated Hospital of Soochow University (2)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1)  ·  Henan Cancer Hospital (1)  ·  Jianfeng Zhou (1)  ·  Mathias Witzens-Harig (1)  ·  Nanfang Hospital, Southern Medical University (1)  ·  Northwestern University (1)  ·  Pusan National University Hospital (1)  ·  Royal Marsden NHS Foundation Trust (1)

Countries

China (14)  ·  Italy (2)  ·  Germany (1)  ·  South Korea (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Michele Spina, MD (2)  ·  Ye Guo, MD (2)  ·  Barbara Pro, MD (1)  ·  Cheolwon Suh, MD, PhD (1)  ·  David Cunningham, MD FRCP (1)  ·  Ho-Jin Ho-Jin (1)  ·  Mathias Witzens-Harig, MD (1)  ·  Qifa Liu (1)  ·  Weili Zhao, Prof (1)  ·  Wenbin Qian (1)  ·  Yanyan Liu, M.D. Ph.D (1)  ·  Yuankai Shi, M.D (1)

Results publications

PMID 18213528, PMID 18824292, PMID 1950172, PMID 20686505, PMID 21390126, PMID 21796119, PMID 22080169, PMID 22339555, PMID 22362161, PMID 23799873, PMID 24721323, PMID 25652253, PMID 25712263, PMID 29748444, PMID 29752199, PMID 32989495, PMID 33097085, PMID 35418080, PMID 38237077

NIH funding

2009 (1), P30CA060553 (1)